Suppr超能文献

蛋白激酶 Cι 在突变型 KRAS 肺腺癌中驱动 NOTCH3 依赖性的干细胞样表型。

Protein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma.

机构信息

Department of Cancer Biology, Mayo Clinic Cancer Center, Jacksonville, FL 32224, USA.

Department of Cancer Biology, Mayo Clinic Cancer Center, Jacksonville, FL 32224, USA.

出版信息

Cancer Cell. 2016 Mar 14;29(3):367-378. doi: 10.1016/j.ccell.2016.02.012.

Abstract

We report that the protein kinase Cι (PKCι) oncogene controls expression of NOTCH3, a key driver of stemness, in KRAS-mediated lung adenocarcinoma (LADC). PKCι activates NOTCH3 expression by phosphorylating the ELF3 transcription factor and driving ELF3 occupancy on the NOTCH3 promoter. PKCι-ELF3-NOTCH3 signaling controls the tumor-initiating cell phenotype by regulating asymmetric cell division, a process necessary for tumor initiation and maintenance. Primary LADC tumors exhibit PKCι-ELF3-NOTCH3 signaling, and combined pharmacologic blockade of PKCι and NOTCH synergistically inhibits tumorigenic behavior in vitro and LADC growth in vivo demonstrating the therapeutic potential of PKCι-ELF3-NOTCH3 signal inhibition to more effectively treat KRAS LADC.

摘要

我们报告称,蛋白激酶 Cι(PKCι)癌基因控制 KRAS 介导的肺腺癌(LADC)中NOTCH3 的表达,NOTCH3 是干性的关键驱动因素。PKCι 通过磷酸化 ELF3 转录因子并驱动 ELF3 占据 NOTCH3 启动子来激活 NOTCH3 表达。PKCι-ELF3-NOTCH3 信号通过调节不对称细胞分裂来控制肿瘤起始细胞表型,这是肿瘤起始和维持所必需的过程。原发性 LADC 肿瘤表现出 PKCι-ELF3-NOTCH3 信号,并且联合应用 PKCι 和 NOTCH 的药物阻断在体外协同抑制致瘤行为,体内抑制 LADC 生长,证明了抑制 PKCι-ELF3-NOTCH3 信号以更有效地治疗 KRAS LADC 的治疗潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05d2/4795153/278ffc3b350a/nihms761777f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验